Buy, Sell, Or Hold LLY Stock At $870?

1. Eli Lilly's Q4 earnings exceeded expectations with $5.32 per share. 2. Revenue of $13.5 billion showed 45% y-o-y growth despite a slight miss. 3. Strong demand for Zepbound drove significant sales, but Mounjaro faced pricing challenges. 4. LLY stock has gained 50% year-to-date, outperforming S&P 500 indices. 5. Future outlook estimates $58-61 billion in revenue, indicating potential for growth.